Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
7173 | 1396 | 36.0 | 74% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
336 | 3 | DERMATOLOGY//BEHCETS DISEASE//DERMATOL | 37504 |
1781 | 2 | BEHCETS DISEASE//BEHCETS SYNDROME//THALIDOMIDE | 6366 |
7173 | 1 | THALIDOMIDE//CEREBLON//THALIDOMIDE ANALOGUES | 1396 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | THALIDOMIDE | authKW | 3956006 | 39% | 33% | 548 |
2 | CEREBLON | authKW | 310657 | 2% | 57% | 25 |
3 | THALIDOMIDE ANALOGUES | authKW | 214335 | 1% | 70% | 14 |
4 | CC 5013 | authKW | 145805 | 1% | 67% | 10 |
5 | THALIDOMIDE ENANTIOMERS | authKW | 131231 | 0% | 100% | 6 |
6 | RD GRP PHARMACEUT | address | 112482 | 0% | 86% | 6 |
7 | THALIDOMIDE EMBRYOPATHY | authKW | 107168 | 1% | 70% | 7 |
8 | PHTHALIMIDE | authKW | 100869 | 2% | 14% | 33 |
9 | THALIDOMIDE ANALOGS | authKW | 82433 | 1% | 54% | 7 |
10 | LENALIDOMIDE | authKW | 79900 | 4% | 7% | 55 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Pharmacology & Pharmacy | 1897 | 23% | 0% | 324 |
2 | Dermatology | 1848 | 9% | 0% | 128 |
3 | Chemistry, Medicinal | 1385 | 10% | 0% | 139 |
4 | Oncology | 1119 | 16% | 0% | 228 |
5 | Toxicology | 621 | 7% | 0% | 98 |
6 | Immunology | 541 | 11% | 0% | 155 |
7 | Hematology | 286 | 5% | 0% | 72 |
8 | Chemistry, Organic | 152 | 6% | 0% | 89 |
9 | Medicine, Research & Experimental | 147 | 5% | 0% | 70 |
10 | Infectious Diseases | 110 | 3% | 0% | 48 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | RD GRP PHARMACEUT | 112482 | 0% | 86% | 6 |
2 | MOL PHARMACOL SECT | 65746 | 1% | 15% | 20 |
3 | INTENS CARE MED GEN INTERNAL MED | 43744 | 0% | 100% | 2 |
4 | JEROME LIPPER MYELOMA HEMATOL ONCOL | 43744 | 0% | 100% | 2 |
5 | ORG NANOLIFE INNOVAT | 43744 | 0% | 100% | 2 |
6 | LEADING ION CHANNELS | 32805 | 0% | 50% | 3 |
7 | ANTITUMOR SUBST | 29161 | 0% | 67% | 2 |
8 | GREATER PHOENIX AREA | 29161 | 0% | 67% | 2 |
9 | HANSENS DIS PROGRAMS | 24912 | 1% | 16% | 7 |
10 | TERATOGEN INFORMAT SERV | 24602 | 0% | 38% | 3 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | TERATOLOGY | 3241 | 1% | 1% | 17 |
2 | TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS | 1013 | 0% | 1% | 6 |
3 | INVESTIGATIONAL NEW DRUGS | 839 | 1% | 0% | 10 |
4 | CONGENITAL ANOMALIES | 821 | 0% | 1% | 3 |
5 | IMMUNOPHARMACOLOGY | 793 | 1% | 1% | 7 |
6 | LEPROSY REVIEW | 755 | 1% | 1% | 7 |
7 | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 732 | 2% | 0% | 30 |
8 | ONCOLOGY-NEW YORK | 717 | 1% | 0% | 7 |
9 | SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY | 682 | 0% | 1% | 3 |
10 | BIOMEDICINE & PHARMACOTHERAPY | 648 | 1% | 0% | 11 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | THALIDOMIDE | 3956006 | 39% | 33% | 548 | Search THALIDOMIDE | Search THALIDOMIDE |
2 | CEREBLON | 310657 | 2% | 57% | 25 | Search CEREBLON | Search CEREBLON |
3 | THALIDOMIDE ANALOGUES | 214335 | 1% | 70% | 14 | Search THALIDOMIDE+ANALOGUES | Search THALIDOMIDE+ANALOGUES |
4 | CC 5013 | 145805 | 1% | 67% | 10 | Search CC+5013 | Search CC+5013 |
5 | THALIDOMIDE ENANTIOMERS | 131231 | 0% | 100% | 6 | Search THALIDOMIDE+ENANTIOMERS | Search THALIDOMIDE+ENANTIOMERS |
6 | THALIDOMIDE EMBRYOPATHY | 107168 | 1% | 70% | 7 | Search THALIDOMIDE+EMBRYOPATHY | Search THALIDOMIDE+EMBRYOPATHY |
7 | PHTHALIMIDE | 100869 | 2% | 14% | 33 | Search PHTHALIMIDE | Search PHTHALIMIDE |
8 | THALIDOMIDE ANALOGS | 82433 | 1% | 54% | 7 | Search THALIDOMIDE+ANALOGS | Search THALIDOMIDE+ANALOGS |
9 | LENALIDOMIDE | 79900 | 4% | 7% | 55 | Search LENALIDOMIDE | Search LENALIDOMIDE |
10 | EM12 | 78111 | 0% | 71% | 5 | Search EM12 | Search EM12 |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | NASCA, MR , MICALI, G , CHEIGH, NH , WEST, LE , WEST, DP , (2003) DERMATOLOGIC AND NONDERMATOLOGIC USES OF THALIDOMIDE.ANNALS OF PHARMACOTHERAPY. VOL. 37. ISSUE 9. P. 1307-1320 | 103 | 74% | 6 |
2 | MEIERHOFER, C , DUNZENDORFER, S , WIEDERMANN, CJ , (2001) THEORETICAL BASIS FOR THE ACTIVITY OF THALIDOMIDE.BIODRUGS. VOL. 15. ISSUE 10. P. 681 -703 | 92 | 81% | 43 |
3 | PARAVAR, T , LEE, DJ , (2008) THALIDOMIDE: MECHANISMS OF ACTION.INTERNATIONAL REVIEWS OF IMMUNOLOGY. VOL. 27. ISSUE 3. P. 111-135 | 77 | 75% | 22 |
4 | MATTHEWS, SJ , MCCOY, C , (2003) THALIDOMIDE: A REVIEW OF APPROVED AND INVESTIGATIONAL USES.CLINICAL THERAPEUTICS. VOL. 25. ISSUE 2. P. 342-395 | 94 | 64% | 89 |
5 | DIAMANTI, A , CAPRIATI, T , PAPADATOU, B , KNAFELZ, D , BRACCI, F , CORSETTI, T , ELIA, D , TORRE, G , (2015) THE CLINICAL IMPLICATIONS OF THALIDOMIDE IN INFLAMMATORY BOWEL DISEASES.EXPERT REVIEW OF CLINICAL IMMUNOLOGY. VOL. 11. ISSUE 6. P. 699 -708 | 62 | 70% | 2 |
6 | ERIKSSON, T , BJORKMAN, S , HOGLUND, P , (2001) CLINICAL PHARMACOLOGY OF THALIDOMIDE.EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. VOL. 57. ISSUE 5. P. 365 -376 | 56 | 97% | 138 |
7 | BAIDAS, S , TFAYLI, A , BHARGAVA, P , (2002) THALIDOMIDE: AN OLD DRUG WITH NEW CLINICAL APPLICATIONS.CANCER INVESTIGATION. VOL. 20. ISSUE 5-6. P. 835-848 | 67 | 87% | 8 |
8 | VARGESSON, N , (2015) THALIDOMIDE-INDUCED TERATOGENESIS: HISTORY AND MECHANISMS.BIRTH DEFECTS RESEARCH PART C-EMBRYO TODAY-REVIEWS. VOL. 105. ISSUE 2. P. 140 -156 | 52 | 63% | 14 |
9 | KUMAR, N , SHARMA, U , SINGH, C , SINGH, B , (2012) THALIDOMIDE: CHEMISTRY, THERAPEUTIC POTENTIAL AND OXIDATIVE STRESS INDUCED TERATOGENICITY.CURRENT TOPICS IN MEDICINAL CHEMISTRY. VOL. 12. ISSUE 13. P. 1436 -1455 | 79 | 52% | 12 |
10 | GROVER, JK , VATS, V , GOPALAKRISHNA, R , RAMAM, M , (2000) THALIDOMIDE: A RE-LOOK.NATIONAL MEDICAL JOURNAL OF INDIA. VOL. 13. ISSUE 3. P. 132-141 | 75 | 77% | 6 |
Classes with closest relation at Level 1 |